Last reviewed · How we verify
Standard Lipid-Lowering Therapy
At a glance
| Generic name | Standard Lipid-Lowering Therapy |
|---|---|
| Also known as | Statins ± Ezetimibe |
| Sponsor | Shanghai Zhongshan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC (PHASE1)
- The Belgian REAL (BE.REAL) Registry
- Optimizing Non-statin Agents for ASCVD
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Lipid-Lowering Therapy CI brief — competitive landscape report
- Standard Lipid-Lowering Therapy updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI